Intravenous Minocycline: A Review in Acinetobacter Infections
Sarah L Greig1, Lesley J Scott2
1Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
Abstract:
Intravenous minocycline (Minocin®) is approved in the USA for use in patients with infections due to susceptible strains of Gram-positive and Gram-negative pathogens, including infections due to Acinetobacter spp. Minocycline is a synthetic tetracycline derivative that was originally introduced in the 1960s. A new intravenous formulation of minocycline was recently approved and introduced to address the increasing prevalence of multidrug-resistant (MDR) pathogens. Minocycline shows antibacterial activity against A. baumannii clinical isolates worldwide, and exhibits synergistic bactericidal activity against MDR and extensively drug-resistant (XDR) A. baumannii isolates when combined with other antibacterial agents. In retrospective studies, intravenous minocycline provided high rates of clinical success or improvement and was generally well tolerated among patients with MDR or carbapenem-resistant A. baumannii infections. While randomized clinical trial data would be useful to fully establish the place of minocycline in the management of these infections for which there are currently very few available options, clinical trials in patients with infections due to Acinetobacter spp. are difficult to perform. Nevertheless, current data indicate a potential role for intravenous minocycline in the treatment of patients MDR A. baumannii infections, particularly when combined with a second antibacterial agent (e.g. colistin).
Insights
Intravenous minocycline shows promise for treating multidrug-resistant Acinetobacter baumannii infections. Clinical data suggest it is well-tolerated and effective, especially when combined with other antibiotics.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Acinetobacter baumannii is a significant cause of hospital-acquired infections, often exhibiting multidrug resistance (MDR).
- The emergence of extensively drug-resistant (XDR) A. baumannii necessitates novel therapeutic strategies.
- Intravenous minocycline, a synthetic tetracycline derivative, has been repurposed to address this challenge.
Purpose of the Study:
- To evaluate the efficacy and tolerability of intravenous minocycline in treating MDR and XDR Acinetobacter spp. infections.
- To assess the synergistic activity of minocycline in combination with other antibacterial agents against resistant A. baumannii strains.
- To review current clinical data supporting the use of minocycline for challenging Acinetobacter infections.
Main Methods:
- Review of retrospective studies and clinical data on intravenous minocycline use.
- Assessment of in vitro antibacterial activity and synergistic effects against Acinetobacter baumannii isolates.
- Analysis of clinical outcomes, including success rates and adverse events in patients with MDR/XDR infections.
Main Results:
- Minocycline demonstrates broad antibacterial activity against global A. baumannii clinical isolates.
- Synergistic bactericidal activity was observed when minocycline was combined with other antibiotics against MDR/XDR strains.
- Retrospective studies reported high clinical success or improvement rates with intravenous minocycline in patients with MDR A. baumannii infections, with good tolerability.
Conclusions:
- Intravenous minocycline presents a potential therapeutic option for MDR Acinetobacter baumannii infections.
- Combination therapy, particularly with agents like colistin, may enhance minocycline's effectiveness.
- Further randomized clinical trial data are needed, though challenging to conduct, to solidify minocycline's role in treating these difficult-to-treat infections.
Related Concept Videos
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Estimation of k and VD of Aminoglycosides
Acute Pyelonephritis I: Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Antimicrobial Effectiveness


